Treatment of small cell lung cancer: The state of the art

Lung Cancer

Volumn 17, Issue SUPPL. 1, 1997, Pages

  Murray, Nevin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemotherapy; Combined modality therapy; Radiotherapy; Small cell lung cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; TAMOXIFEN; VINCRISTINE;

CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOXICITY; HUMAN; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS;

EID: 0030983413     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00641-7     Document Type: Conference Paper

References (42)

1. Eddy DM. A manual for assessing health practices and designing practice policies: the explicit approach. Philadelphia, PA: American College of Physicians, 1992.
2. Pignon JP, Arriagada R, Ihde DC. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618-1624.
3. Murray N, Coy P, Pater JL. Importance of timing of thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11: 336-344.
4. Ihde DH. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-1441.
5. Goldie JG, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733.
6. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9: 499-508.
7. Cohen MH, Creaven PJ, Fossieck BE. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 349-354.
8. Skipper HE. Dose intensity versus total dose of chemotherapy: an experimental basis. In: De Vita V, Hellman S, Rosenberg S, editors. Important Advances in Oncology. Philadelphia: PA, Lippincott 1990: 43-64.
9. Coppin C. A model of chemotherapy delivery: predictions and clinical realities. In: Kimura D, Yamada D, Carter SK, editors. Cancer Chemotherapy: Challenges for the Future (vol 5). Tokyo: Japan Excerpta Medica, 1990: 67-64.
10. Coldman A. Dose intensive chemotherapy and the development of resistance to anticancer agents. In: Kimura D, Yamada K, Carter SK, editors. Cancer Chemotherapy: Challenges for the Future (vol 5). Tokyo: Japan, Excerpta Medica, 1990: 41-48.
11. Skipper HE, Schabel FM Jr., Mellet LB. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970; 54: 431-450.
12. Johnson DH, Einhom LH, Birch R. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin and vincristine for extensive-stage small-cell lung cancer: a phase III trial for the Southeastern Cancer Study Group. J Clin Oncol 1987; 5: 1731-1738.
13. Figueredo AT, Hryniuk WM, Strautmanis I. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3: 54-64.
14. Ihde DC, Mulshine JL, Kramer BS. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12: 2022-2034.
15. Mehta C, Vogl SE. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: minor improvements in rate of remission and survival [abstract no. 612]. Proc Am Assoc Cancer Res 1982; 23: 155.
16. LeChevalier, Arrigada R, Pignon JP. Initial chemotherapy doses have a significant impact on survival in limited small cell lung cancer - results of a multicentric prospective randomized study in 105 patients. N Engl J Med 1993; 329: 1848-1852.
17. Spiro SG, Souhami RL, Geddes DM. Duration of chemotherapy in small cell lung cancer: a cancer research campaign trial. Br J Cancer 1989; 59: 578-583.
18. Medical Council Research Lung Working Party: controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989; 59: 584-590.
19. Giaccone G, Dalesio O, McVie G. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 1993; 11: 1230-1240.
20. DeVita VT, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment for cancer. Cancer 1975; 35: 98-110.
21. Hansen HH, Dombernowsky MD, Hansen M. Chemotherapy of advanced small-cell anaplastic carcinoma: superiority of a four-drug combination to a three-drug combination. Ann Int Med 1978; 89: 177-181.
22. Messeih AA, Schweitzer JM, Lipton A. Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 1987; 71: 61-66.
23. Jackson DV, Case LD, Zekan PJ. Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 1988; 6: 1161-1169.
24. Jett JR, Everson L, Therneau TM. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol 1990; 8: 33-39.
25. Loehrer PJ, Ansari R, Gonin R. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13: 2494-2599.
26. Miyamoto H, Nakabayashi T, Isobe H. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992; 49: 431-435.
27. Einhorn LH, Crawford J, Birch R. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small-cell lung cancer. J Clin Oncol 1988; 6: 451-456.
28. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 1982; 66: 439-449.
29. Roth BJ, Johnson DH, Einhorn LH. Randomized study of cyclophosphamide plus doxorubicin plus vincristine versus etoposide plus cisplatin versus alternation of these two regimens in extensive small cell lung cancer: a phase III study of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
30. Fukuoka M, Furuse K, Saijo N. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-861.
31. Evans WK, Feld R, Murray N. Superiority of alternating non-cross-resistant chemotherapy in extensive stage small cell lung cancer. Ann Intern Med 1987; 107: 451-458.
32. Feld R, Evans WK, Coy P. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross resistant chemotherapy combinations in patients with limited small cell carcinoma of the lung. J Clin Oncol 1987; 5: 1401-1409.
33. Goodman GE, Crowley JJ, Blasko JC. Treatment of limited small cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol 1990; 8: 39-47.
34. Murray N, Hadzic E, Shah A. Alternating chemotherapy and thoracic irradiation with concurrent cisplatin-etoposide for limited stage small cell lung cancer [abstract no. 835]. Proc Am Soc Clin Oncol 1984; 3: 214.
35. Bunn PA, Crowley J, Kelly K. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632-1641.
36. McCracken JD, Janaki LM, Crowley JJ. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group study. J Clin Oncol 1990; 8: 892-898.
37. Turrisi A. Limited small cell lung cancer (LSCLC): concurrent BID thoracic radiotherapy (TRT) with platinum-etoposide (PE): an ECOG study [abstract no. 887], Proc Am Soc Clin Oncol 1990; 9: 230.
38. Takada M, Fukuoka M, Furuse K. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: preliminary results of the Japan Clinical Oncology Group [abstract no. 1103]. Proc Am Soc Clin Oncol 1996; 15: 372.
39. Clark PI for the MRC Lung Cancer Working Party. Oral etoposide alone is inadequate palliative chemotherapy for small cell lung cancer [abstract no. 1124]. Proc Am Soc Clin Oncol 1996; 15: 377.
40. Siu L, Shepherd F, Murray N. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996; 14: 821-828.
41. Westeel V, Murray N, Gelmon K. Pilot study of cisplatin, doxorubicin, vincristine and etoposide (PAVE) in elderly and frail patients with small-cell lung cancer (SCLC) [abstract no. 1125]. Proc Am Soc Clin Oncol 1996; 11: 377.
42. Murray N, Grafton C, Shah A. Abbreviated treatment for elderly and infirm patients with limited stage small cell lung cancer [abstract no. 660]. Lung Cancer 1994; 11: 171.